| Alicia Erin Bennett, | |
|
100 Health Park Drive, Louisville, CO 80027 | |
| (303) 673-1000 | |
| (303) 306-7753 |
| Full Name | Alicia Erin Bennett |
|---|---|
| Gender | Female |
| Speciality | Neurology |
| Experience | 13 Years |
| Location | 100 Health Park Drive, Louisville, Colorado |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023317633 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084N0400X | Psychiatry & Neurology - Neurology | 036-149178 (Illinois) | Secondary |
| 2084N0400X | Psychiatry & Neurology - Neurology | DR.0056510 (Colorado) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hca-healthone Dba Swedish Medical Center | Englewood, CO | Hospital |
| Saint Joseph Hospital | Denver, CO | Hospital |
| Lutheran Medical Center | Wheat ridge, CO | Hospital |
| Sky Ridge Medical Center | Lone tree, CO | Hospital |
| Presbyterian St Luke's Medical Center | Denver, CO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Blue Sky Telehealth Llc | 5395155964 | 36 |
| Carepoint Inpatient Blue Sky Neurology Pllc | 9436456118 | 33 |
| Wellspan Medical Group | 1951213115 | 1946 |
| Asante Physician Partners | 8325206246 | 229 |
| Carepoint Inpatient Blue Sky Neurology - Texas, Pllc | 1557776036 | 30 |
News Archive
Merck & Co., Inc. announced today that in new Phase III data, GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] was 77.5 percent (95 percent CI: 39.6, 93.3) efficacious against anal intraepithelial neoplasia (AIN) associated with human papillomavirus (HPV) types 6, 11, 16 and 18 in 16-to-26 year-old men who have sex with men. The data were presented at the European Research Organization on Genital Infection and Neoplasia (EUROGIN) conference in Monte Carlo, Monaco.
Bristol-Myers Squibb Company today announced results from a Phase II study in which treatment with an all-oral, dual direct-acting antiviral (DAA) regimen of daclatasvir, an investigational NS5A replication complex inhibitor, and asunaprevir, an investigational NS3 protease inhibitor, achieved undetectable viral load 24 weeks post-treatment (SVR24) in 77% (33/43) of difficult-to-treat genotype 1b hepatitis C (HCV) patients.
A foundational study published in top biomedical journal PNAS (Proceedings of the National Academy of Sciences) this week by researchers at the University of Toronto's Institute of Biomaterials & Biomedical Engineering and the McEwen Centre for Regenerative Medicine have identified the optimal structure and cell ratio associated with heart function - and the discovery has already led the team to another research first: the engineering of the first-ever living, three-dimensional human arrhythmic tissue.
An assistant professor at the University of California, Riverside's Bourns College of Engineering has recently received a $360,000 grant to better organize enzymes on electrodes to create nanoscale devices that more efficiently convert the chemical energy of sugars and complex carbohydrates in to electricity.
› Verified 8 days ago
| Entity Name | Carepoint Inpatient Blue Sky Neurology Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568833713 PECOS PAC ID: 9436456118 Enrollment ID: O20160323001467 |
News Archive
Merck & Co., Inc. announced today that in new Phase III data, GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] was 77.5 percent (95 percent CI: 39.6, 93.3) efficacious against anal intraepithelial neoplasia (AIN) associated with human papillomavirus (HPV) types 6, 11, 16 and 18 in 16-to-26 year-old men who have sex with men. The data were presented at the European Research Organization on Genital Infection and Neoplasia (EUROGIN) conference in Monte Carlo, Monaco.
Bristol-Myers Squibb Company today announced results from a Phase II study in which treatment with an all-oral, dual direct-acting antiviral (DAA) regimen of daclatasvir, an investigational NS5A replication complex inhibitor, and asunaprevir, an investigational NS3 protease inhibitor, achieved undetectable viral load 24 weeks post-treatment (SVR24) in 77% (33/43) of difficult-to-treat genotype 1b hepatitis C (HCV) patients.
A foundational study published in top biomedical journal PNAS (Proceedings of the National Academy of Sciences) this week by researchers at the University of Toronto's Institute of Biomaterials & Biomedical Engineering and the McEwen Centre for Regenerative Medicine have identified the optimal structure and cell ratio associated with heart function - and the discovery has already led the team to another research first: the engineering of the first-ever living, three-dimensional human arrhythmic tissue.
An assistant professor at the University of California, Riverside's Bourns College of Engineering has recently received a $360,000 grant to better organize enzymes on electrodes to create nanoscale devices that more efficiently convert the chemical energy of sugars and complex carbohydrates in to electricity.
› Verified 8 days ago
| Entity Name | St Lukes Clinic-treasure Valley Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326336058 PECOS PAC ID: 4981878402 Enrollment ID: O20180418000510 |
News Archive
Merck & Co., Inc. announced today that in new Phase III data, GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] was 77.5 percent (95 percent CI: 39.6, 93.3) efficacious against anal intraepithelial neoplasia (AIN) associated with human papillomavirus (HPV) types 6, 11, 16 and 18 in 16-to-26 year-old men who have sex with men. The data were presented at the European Research Organization on Genital Infection and Neoplasia (EUROGIN) conference in Monte Carlo, Monaco.
Bristol-Myers Squibb Company today announced results from a Phase II study in which treatment with an all-oral, dual direct-acting antiviral (DAA) regimen of daclatasvir, an investigational NS5A replication complex inhibitor, and asunaprevir, an investigational NS3 protease inhibitor, achieved undetectable viral load 24 weeks post-treatment (SVR24) in 77% (33/43) of difficult-to-treat genotype 1b hepatitis C (HCV) patients.
A foundational study published in top biomedical journal PNAS (Proceedings of the National Academy of Sciences) this week by researchers at the University of Toronto's Institute of Biomaterials & Biomedical Engineering and the McEwen Centre for Regenerative Medicine have identified the optimal structure and cell ratio associated with heart function - and the discovery has already led the team to another research first: the engineering of the first-ever living, three-dimensional human arrhythmic tissue.
An assistant professor at the University of California, Riverside's Bourns College of Engineering has recently received a $360,000 grant to better organize enzymes on electrodes to create nanoscale devices that more efficiently convert the chemical energy of sugars and complex carbohydrates in to electricity.
› Verified 8 days ago
| Entity Name | Blue Sky Telehealth Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649886458 PECOS PAC ID: 5395155964 Enrollment ID: O20211115001970 |
News Archive
Merck & Co., Inc. announced today that in new Phase III data, GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] was 77.5 percent (95 percent CI: 39.6, 93.3) efficacious against anal intraepithelial neoplasia (AIN) associated with human papillomavirus (HPV) types 6, 11, 16 and 18 in 16-to-26 year-old men who have sex with men. The data were presented at the European Research Organization on Genital Infection and Neoplasia (EUROGIN) conference in Monte Carlo, Monaco.
Bristol-Myers Squibb Company today announced results from a Phase II study in which treatment with an all-oral, dual direct-acting antiviral (DAA) regimen of daclatasvir, an investigational NS5A replication complex inhibitor, and asunaprevir, an investigational NS3 protease inhibitor, achieved undetectable viral load 24 weeks post-treatment (SVR24) in 77% (33/43) of difficult-to-treat genotype 1b hepatitis C (HCV) patients.
A foundational study published in top biomedical journal PNAS (Proceedings of the National Academy of Sciences) this week by researchers at the University of Toronto's Institute of Biomaterials & Biomedical Engineering and the McEwen Centre for Regenerative Medicine have identified the optimal structure and cell ratio associated with heart function - and the discovery has already led the team to another research first: the engineering of the first-ever living, three-dimensional human arrhythmic tissue.
An assistant professor at the University of California, Riverside's Bourns College of Engineering has recently received a $360,000 grant to better organize enzymes on electrodes to create nanoscale devices that more efficiently convert the chemical energy of sugars and complex carbohydrates in to electricity.
› Verified 8 days ago
| Entity Name | Carle West Physician Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467074138 PECOS PAC ID: 8921420308 Enrollment ID: O20230504000908 |
News Archive
Merck & Co., Inc. announced today that in new Phase III data, GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] was 77.5 percent (95 percent CI: 39.6, 93.3) efficacious against anal intraepithelial neoplasia (AIN) associated with human papillomavirus (HPV) types 6, 11, 16 and 18 in 16-to-26 year-old men who have sex with men. The data were presented at the European Research Organization on Genital Infection and Neoplasia (EUROGIN) conference in Monte Carlo, Monaco.
Bristol-Myers Squibb Company today announced results from a Phase II study in which treatment with an all-oral, dual direct-acting antiviral (DAA) regimen of daclatasvir, an investigational NS5A replication complex inhibitor, and asunaprevir, an investigational NS3 protease inhibitor, achieved undetectable viral load 24 weeks post-treatment (SVR24) in 77% (33/43) of difficult-to-treat genotype 1b hepatitis C (HCV) patients.
A foundational study published in top biomedical journal PNAS (Proceedings of the National Academy of Sciences) this week by researchers at the University of Toronto's Institute of Biomaterials & Biomedical Engineering and the McEwen Centre for Regenerative Medicine have identified the optimal structure and cell ratio associated with heart function - and the discovery has already led the team to another research first: the engineering of the first-ever living, three-dimensional human arrhythmic tissue.
An assistant professor at the University of California, Riverside's Bourns College of Engineering has recently received a $360,000 grant to better organize enzymes on electrodes to create nanoscale devices that more efficiently convert the chemical energy of sugars and complex carbohydrates in to electricity.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Alicia Erin Bennett, P.o. Box 17326, Denver, CO 80217-7326 Ph: (303) 306-7783 | Alicia Erin Bennett, 100 Health Park Drive, Louisville, CO 80027 Ph: (303) 673-1000 |
News Archive
Merck & Co., Inc. announced today that in new Phase III data, GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] was 77.5 percent (95 percent CI: 39.6, 93.3) efficacious against anal intraepithelial neoplasia (AIN) associated with human papillomavirus (HPV) types 6, 11, 16 and 18 in 16-to-26 year-old men who have sex with men. The data were presented at the European Research Organization on Genital Infection and Neoplasia (EUROGIN) conference in Monte Carlo, Monaco.
Bristol-Myers Squibb Company today announced results from a Phase II study in which treatment with an all-oral, dual direct-acting antiviral (DAA) regimen of daclatasvir, an investigational NS5A replication complex inhibitor, and asunaprevir, an investigational NS3 protease inhibitor, achieved undetectable viral load 24 weeks post-treatment (SVR24) in 77% (33/43) of difficult-to-treat genotype 1b hepatitis C (HCV) patients.
A foundational study published in top biomedical journal PNAS (Proceedings of the National Academy of Sciences) this week by researchers at the University of Toronto's Institute of Biomaterials & Biomedical Engineering and the McEwen Centre for Regenerative Medicine have identified the optimal structure and cell ratio associated with heart function - and the discovery has already led the team to another research first: the engineering of the first-ever living, three-dimensional human arrhythmic tissue.
An assistant professor at the University of California, Riverside's Bourns College of Engineering has recently received a $360,000 grant to better organize enzymes on electrodes to create nanoscale devices that more efficiently convert the chemical energy of sugars and complex carbohydrates in to electricity.
› Verified 8 days ago
Dr. David Ethan Miller, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 400 S Mccaslin Blvd Ste 110, Louisville, CO 80027 Phone: 720-279-9682 Fax: 720-279-9687 | |
Dr. Brian Alexander Anderson, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 2255 S 88th St, Louisville, CO 80027 Phone: 303-666-2095 Fax: 303-666-1801 | |
Dr. Allison Rachel Gray, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 275 Century Cir Ste 100, Louisville, CO 80027 Phone: 720-738-8738 Fax: 720-862-2184 | |
Dr. Roderick Shields O'brien, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2255 S 88th St, Louisville, CO 80027 Phone: 303-673-9990 | |
Dr. Marcy Cooper, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1314 Main St Unit 204, Louisville, CO 80027 Phone: 303-666-0443 Fax: 303-666-7505 | |
Dr. Kytja K.s. Voeller, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 363 Centennial Pkwy Ste 110, Louisville, CO 80027 Phone: 303-442-4750 Fax: 303-443-4682 |